A study comparing how well Propolis (a natural bee product) works compared to Triamcinolone acetonide (a commonly used steroid medicine) when applied to the mouth to treat painful symptoms of oral lichen planus. Participants were randomly given one of the two treatments to see which worked better

INTERVENTION: Intervention1: Topical propolis gel: Oral lichen planus Patients in Group I will be given Topical Propolis to apply on the affected site 3 times a day for 15 days The active treatment duration for each group will be for a period of 15 days. The patients will be recalled and scheduled for an appointment on 7th and 15th day and the clinical evaluation will be done and recorded. Regular telephonic calls as a reminder for recall appointments will be made to avoid patient drop out on follow-up. The following clinical parameters were assessed during follow-up: 1.Pain 2.Erythema and ulceration: 3.MOMI Side effects Control Intervention1: Topical 0.1% Triamcinolone acetonide gel: Patients in Group II will be given Topical 0.1% Triamcinolone acetonide to apply on the affected site 3 times a day for 15 days The active treatment duration for each group will be for a period of 15 days. The patients will be recalled and scheduled for an appointment on 7th and 15th day and the clinical evaluation will be done and recorded. Regular telephonic calls as a reminder for recall appointments will be made to avoid patient drop out on follow-up. The following clinical parameters were assessed during follow-up: 1.Pain: NRS 2.Erythema and ulceration: 3.MOMI Side effects, CONDITION: Health Condition 1: K137- Other and unspecified lesions of oral mucosa, PRIMARY OUTCOME: To evaluate the efficacy of topical propolis in comparison with topical triamcinolone acetonide in symptomatic oral lichen planus in following parameters ; 1. Pain ; 2. Erythema and ulceration ; 3. Side effects ; Timepoint: The active treatment duration for each group will be for a period of 15 days. The patients will be recalled and scheduled for an appointment on 7th and 15th day and the clinical evaluation will be done and recorded., SECONDARY OUTCOME: NILTimepoint: NIL, INCLUSION CRITERIA: 1 Patients with clinically diagnosed atrophic/erosive OLP(based on modified WHO clinical criteria, 2003) 2 Individuals willing to be a part of the study, who sign the informed consent form, and who find it convenient to appear for follow-ups as required by the study. 3 Patients who had not used systemic or topical glucocorticosteroids for at least the past 2 weeks 4 Patients who agree not to use any other medication such as analgesics and Anesthetics in either topical form or systemic form during the study.